Erythropoietin use in peritoneal dialysis patients.
Erythropoietin (Epo) is currently used less extensively in peritoneal dialysis (PD) patients than in hemodialysis (HD) patients. Early data suggest that Epo is equally effective in PD patients, and that the risk profile is similar. No adverse consequences to the dialysis procedure or peritonitis rates have been consistently noted. It has been suggested that PD patients may require less Epo than their HD counterparts, but this is unproven. Further research on the preferred route of administration and timing of the dosing is necessary.
Department of Medicine, University of Wisconsin, Madison.
S W
SW
Zimmerman
C A
CA
Johnson
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010530:Peritoneal Dialysis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin